Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

Net Loss Per Share

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Net Loss Per Share

11.

Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Numerator:
Net loss	$	(5,777,966	)	$	(4,639,939	)	$	(10,255,744	)	$	(9,280,540	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		5,226,101			4,224,294			4,918,206			4,222,496
Net loss per share applicable to common stockholders – basic and diluted	$	(1.11	)	$	(1.10	)	$	(2.09	)	$	(2.20	)

Note that the net loss per share computations for all periods presented reflect the changes in the number of shares resulting from the 1 for 6 reverse stock split that was approved by shareholders on June 23, 2023 and became effective as of June 30, 2023. The number of shares of common stock issued and outstanding immediately before the reverse stock split was 31,626,238; the number of shares outstanding immediately after the reverse split was 5,290,826, a decrease of 26,335,412 shares.

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Six Months Ended June 30,
	2023		2022
Options to purchase shares of stock		835,913		672,900
Warrants to purchase shares of stock		3,137,590		260,319
Total		3,973,503		933,219